EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A User‐Driven Framework for Dose Selection in Pregnancy: Proof of Concept for Sertraline

Charlotte Koldeweij iD, Caroline Dibbets iD, Bryony D Franklin, Hubertina C J Scheepers, Saskia N de Wildt iD

Clinical Pharmacology & Therapeutics · 2025-01 · 117 (1) · 214-224

DOI: 10.1002/cpt.3429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 09.09.2024. Verfasst von Charlotte Koldeweij und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Sertraline. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KNAW Van Leersum Grant/KNAW Medical Sciences Fund 2022, Royal Netherlands Academy of Arts & Sciences, National Institute for Health and Care Research (NIHR) North West London Patient Safety Research Collaboration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite growing knowledge of pregnancy‐induced changes in physiology that may alter maternal and fetal pharmacokinetics, evidence‐based antenatal doses are lacking for most drugs. Pharmacokinetic modeling and expanding clinical data in pregnancy may support antenatal doses. We aimed to develop and pilot a comprehensive and user‐driven Framework for Dose Selection in Pregnancy to support the clinical implementation of a best‐evidence antenatal dose for sertraline. After initial development and evaluation by experts, the framework prototype was piloted to formulate an antenatal dosing strategy for sertraline in depression and anxiety disorders. Next, the framework was reviewed and assessed for usability by a multidisciplinary working committee of end‐users comprising healthcare practitioners, experts from other disciplines including pharmacometrics, reproductive toxicology and medical ethics, alongside pregnant women and a partner. The resulting framework encompasses the following: rationale for drug selection, a comprehensive analysis of pharmacokinetic and dose‐related efficacy and safety data, and implementation aspects including feasibility and desirability of the recommended antenatal dose based on a structured maternal and fetal benefit–risk assessment. An antenatal dose recommendation for sertraline, as a case study, was formulated using this approach and endorsed for clinical use by the working committee. Future applications of the framework for other drugs can further demonstrate its suitability for developing best evidence, acceptable and clinically feasible antenatal doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SertralineHumansPregnancyFemalePregnancy ComplicationsPilot ProjectsProof of Concept StudyDose-Response Relationship, DrugSelective Serotonin Reuptake InhibitorsRisk AssessmentAnxiety DisordersAntidepressive Agents

Substanzen

SertralineSelective Serotonin Reuptake InhibitorsAntidepressive Agents

Autor:innen und Institutionen

  • Division of Pharmacology and Toxicology, Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Obstetrics and Gynaecology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Centre for Medication Safety and Service Quality, Imperial College Healthcare NHS Trust, London, UK.
  • Department of Practice and Policy, UCL School of Pharmacy, London, UK.
  • Grow, School for Oncology and Reproduction, Maastricht, The Netherlands.
  • Department of Pediatric and Neonatal Intensive Care, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.

ORCID-Profile: Charlotte Koldeweij, Caroline Dibbets, Saskia N de Wildt

Förderung

  • KNAW Van Leersum Grant/KNAW Medical Sciences Fund 2022
  • Royal Netherlands Academy of Arts & Sciences
  • National Institute for Health and Care Research (NIHR) North West London Patient Safety Research Collaboration
  • Gates Foundation
  • Bill and Melinda Gates Foundation
  • National Institute for Health and Care Research

Zitieren

APA

Koldeweij, C., Dibbets, C., Franklin, B. D., Scheepers, H. C. J., & de Wildt, S. N. (2025). A User‐Driven Framework for Dose Selection in Pregnancy: Proof of Concept for Sertraline. Clinical Pharmacology & Therapeutics, 117(1), 214-224. https://doi.org/10.1002/cpt.3429

Vancouver

Koldeweij C, Dibbets C, Franklin BD, Scheepers HCJ, de Wildt SN. A User‐Driven Framework for Dose Selection in Pregnancy: Proof of Concept for Sertraline. Clinical Pharmacology & Therapeutics. 2025;117(1):214-224. doi:10.1002/cpt.3429

BibTeX
@article{Koldeweij2025,
  author = {Koldeweij, Charlotte and Dibbets, Caroline and Franklin, Bryony D and Scheepers, Hubertina C J and de Wildt, Saskia N},
  title = {A User‐Driven Framework for Dose Selection in Pregnancy: Proof of Concept for Sertraline},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {1},
  pages = {214--224},
  doi = {10.1002/cpt.3429}
}
Kostenlos starten →